FOX News: Business
FOXBusiness.com - Breaking news and video. Latest Current News: News, Investing, Technology, Personal Finance, Business Leaders, Travel, On Air, Small Business.
Updated: 24 min 23 sec ago
Secondary offerings are common in the biotech world. How should investors react when one is announced?
Disney World's fourth theme park is getting ready to open Pandora next summer, but navigating to the Pacific Islands would've been the smarter play given the success of "Moana" this past weekend.
HealthEquity, UnitedHealth Group, and St. Jude Medical stand out as winners from the unraveling of Obamacare.
If you're gearing up to retire next year, here are some tax moves you don't want to wait on.
Improving operations and higher oil prices have pushed the stock up over 1,000% in the last year. It's time to sell.
Pilgrim's Pride Corp. announced Tuesday a deal to buy GNP Company, a branded-chicken products provider for the upper midwest, for $350 million in cash.
Home prices set a record in September, marking an end to a decade long boom and bust in the housing market that caused some 9 million Americans to lose their homes.
These biopharma stocks have great prospects and can be purchased today at attractive prices.
Momenta Pharmaceuticals Inc. shares jumped 9.7% in pre-market trade Tuesday after the company said a phase 3 clinical trial for its Humira biosimilar met its primary endpoint.
Passive investing has a place in every well-balanced portfolio.
Shares of Nivalis Therapeutics Inc. plunged 53% toward a record low in premarket trade Tuesday, after a Phase 2 trial of its cystic fibrosis treatment failed its primary endpoint.
The U.S. economy grew faster than initially thought in the third quarter, notching its best performance in two years, buoyed by strong consumer spending and a surge in soybean exports.
Is it worth rolling the dice on Flexion and Synergy?
Celldex's volatility continues with a double-digit move lower on Monday.
Bigger might be better for income investors in 2017.
One analyst thinks Apple's iPhone margins will come down during its next product cycle.
U.S. stock index futures were slightly higher on Tuesday, a day after stocks posted their worst performance in nearly a month, with investors awaiting a raft of economic data including GDP numbers.
Diplomat Pharmacy needs to address two big issues next year to rebound. Can the specialty pharmacy do it?
Tiffany & Co reported its first rise in sales in eight quarters as strong sales in China and Japan more than offset a decline in the United States.
News that Juno Therapeutics has halted its lead CAR-T trial again because of safety concerns could mean Kite Pharma is investor's best bet to play this novel approach to fighting back against cancer.